Are HIV-infected patients candidates for liver transplantation?

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 697-707

  Samuel, Didier ^a,b,c   Weber, Rainer ^d   Stock, Peter ^e   Duclos Vallée, Jean Charles ^a,b,c   Terrault, Norah ^e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EFAVIRENZ; EMTRICITABINE; HEPATITIS B ANTIBODY; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PROTEINASE INHIBITOR; RAPAMYCIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TELBIVUDINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; GRAFT REJECTION; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MITOCHONDRIAL TOXICITY; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION;

EID: 40949161351     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.02.009     Document Type: Review

References (52)

1. UNAIDS/WHO. AIDS epidemic update: December 2007. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS and World Health Organization, 2007.
2. Mathers C.D., and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 (2006) e442
3. Weber R., Sabin C.A., Friis-Moller N., Reis P., El-Sadr W.M., Kirk O., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Int Med 166 (2006) 1632-1641
4. Steinbrook R. One step forward, two steps back - will there ever be an AIDS vaccine?. N Engl J Med 357 (2007) 2653-2655
5. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44 (2006) S6-S9
6. Koziel M.J., and Peters M.G. Viral hepatitis in HIV infection. N Engl J Med 356 (2007) 1445-1454
7. Vallet-Pichard A., and Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 44 (2006) S28-S34
8. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palù G., et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 (2005) 615-624
9. Rockstroh J.K., Mocroft A., Soriano V., Tural C., Losso M.H., Horban A., et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192 (2005) 992-1002
10. Greub G., Ledergerber B., Battegay M., Grob P., Perrin L., Furrer H., et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 356 (2000) 1800-1805
11. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., Juriaans S., Weel J., Van Leeuven R., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. Aids 14 (2000) 2895-2902
12. Qurishi N., Kreuzberg C., Luchters G., Lüchters G., Effenberger W., Kupfer B., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362 (2003) 1708-1713
13. Zinkernagel A.S., von Wyl V., Ledergerber B., Rickenbach M., Furrer H., Battegay M., et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 11 (2006) 131-142
14. Levy V., and Grant R.M. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 43 (2006) 904-910
15. Sulkowski M.S., Thomas D.L., Chaisson R.E., and Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283 (2000) 74-80
16. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 44 (2006) S132-S139
17. Schenker S., Martin R.R., and Hoyumpa A.M. Antecedent liver disease and drug toxicity. J Hepatol 31 (1999) 1098-1105
18. Mocroft A., Soriano V., Rockstroh J., Reiss P., Kirk O., De Wit S., et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. Aids 19 (2005) 2117-2125
19. Maida I., Nunez M., Rios M.J., Martin-Carbonero L., Sotgiu G., Toro C., et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 42 (2006) 177-182
20. Mallet V., Blanchard P., Verkarre V., Vallet-Pichard A., Fontaine H., Lascoux-Combe C., et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. Aids 21 (2007) 187-192
21. Ragni M.V., Belle S.H., Im K., Neff G., Roland M., Stock P., et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 188 (2003) 1412-1420
22. Neff G.W., Bonham A., Tzakis A.G., Ragni M., Jayaweera D., Schiff E.R., et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 9 (2003) 239-247
23. Stock P.G., Roland M.E., Carlson L., Freise C.E., Roberts J.P., Hirose R., et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76 (2003) 370-375
24. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
25. Calabrese L.H., Albrecht M., Young J., McCarthy P., Haug P., Jarcho J., et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 348 (2003) 2323-2328
26. Terrault N.A., Carter J.T., Carlson L., Roland M.E., and Stock P.G. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 12 (2006) 801-807
27. Duclos-Vallee J.C., Feray C., Sebagh M., Teicher E., Roque-Afonso A.M., Roche B., et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 47 (2008) 407-417
28. Bhagat V., Foont J.A., Schiff E.R., and Regev A. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl 14 (2008) 92
29. Duclos-Vallée J.C., Vittecoq D., Teicher E., Feray C., Roque-Afonso A.M., Lombes A., et al. HCV viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV coinfected patients. J Hepatol 42 (2005) 341-349
30. De Vera M.E., Dvorchik I., Tom K., Eghtesad B., Thai N., Shakil O., et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transpl 6 (2006) 2983-2993
31. Pineda J.A., Garcia-Garcia J.A., Aguilar-Guisado M., Rios-Villegas M.J., Ruiz-Morales J., Rivero A., et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46 (2007) 622-630
32. McGovern B., Golan Y., Lopez M., Pratt D., Lawton A., Moore G., et al. The impact of cirrhosis on CD4 T cell counts in HIV-seronegative patients. Clin Infect Dis 44 (2007) 431-437
33. Benhamou Y., Di Martino V., Bochet M., Colombet C., Thibault V., Liou M., et al. Factors affecting liver fibrosis in human immunodeficiency virus-and-hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 (2001) 283-287
34. Schreibman I., Gaynor J.J., Jayaweera D., Pyrsopoulos N., Weppler D., Tzakis A., et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 84 (2007) 697-705
35. Roche B., and Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hep 14 (2007) 89-96
36. Berenguer M., Royuela A., and Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 13 (2007) 21-29
37. Frassetto L., Baluom M., Jacobsen W., Christians U., Roland M.E., Stock P.G., et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 80 (2005) 13-17
38. Teicher E., Vincent I., Bonhomme-Faivre L., Abbara C., Barrail A., Boissonnas A., et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 46 (2007) 941-952
39. Roland M.E., Barin B., Carlson L., Frassetto L.A., Terrault N.A., Hirose R., et al. HIV-infected liver and kidney transplant recipients: 1- and 3-Year Outcomes. Am J Transplant 8 (2008) 355-365
40. Castells L., Escartin A., Bilbao I., Len O., Allende H., Vargas V., et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation 83 (2007) 354-358
41. Ragni M.V., Eghtesad B., Schlesinger K.W., Dvorchik I., and Fung J.J. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 11 (2005) 1425-1430
42. Pineda J.A., Romero-Gomez M., Diaz-Garcia F., Giron-Gonzalez J.A., Montero J.L., Torre-Cisneros J., et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41 (2005) 779-789
43. Soriano V., Puoti M., Bonacini M., Brook G., Cargnel A., Rockstroh J., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. Aids 19 (2005) 221-240
44. Norris S., Taylor C., Muiesan P., Portmann B.C., Knisely A.S., Bowles M., et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 10 (2004) 1271-1278
45. Fung J., Eghtesad B., Patel-Tom K., DeVera M., Chapman H., and Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 10 (2004) S39-S53
46. Duclos-Vallee J.C., Feray C., Sebagh M., Teicher E., Roque-Afonso A.M., Roche B., et al. Liver transplantation of HIV-HCV and HIV-HBV coinfected patients:A large experience in a single centre. J Hepatol 44 (2006) S8
47. Coffin C., Berg C., Dove L., Poordad F., Curry M., Regenstein F., et al. Survival and risk of hepatitis B virus recurrence in HIV-HBV coinfected liver transplant recipients: interim findings from the HIV-TR study. Hepatology 46 (2007) 245A
48. Wojcik K., Vogel M., Voigt E., Speidel N., Kalff J.C., Goldmann G., et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. Aids 21 (2007) 1363-1365
49. Vennarecci G., Ettorre G.M., Antonini M., Santoro R., Perracchio L., Visco G., et al. Liver transplantation in HIV-positive patients. Transplant Proc 39 (2007) 1936-1938
50. Castells L., Esteban J.I., Bilbao I., Vargas V., Allende H., Ribera E., et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther 11 (2006) 1061-1070
51. Miró J, Montejo M, Castells L, Rafecas A, Salcedo M, Fortún J, et al. Prognostic Factors of Mortality in HCV/HIV Coinfected Liver Transplant Recipients From the FIPSE OLT-HIV-05 - GESIDA 45-05 Cohort Study (2002-06). 15th CROI Meeting, Boston, MA, 2008, p. 177.
52. Frassetto L.A., Browne M., Cheng A., Wolfe A.R., Roland M.E., Stock P.G., et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 7 (2007) 2816-2820